The AGN properties of the starburst galaxy NGC 7582

NGC 7582 was identified as a Starburst galaxy in the optical \cite[(Veron et al. 1981)]{Veron et al.(1981)} but its X-Ray emission is typical of a Seyfert 1 galaxy \cite[(Ward et al. 1978)]{Ward et al.(1978)}. We analyzed a datacube of this object obtained with the GMOS-IFU on the Gemini-South telescope. After a subtraction of the stellar component using the {\sc starlight} code \cite[(Cid Fernandes et al. 2005)]{Cid Fernandes et al. (2005)}, we looked for optical signatures of the AGN. We detected a broad $H\alpha$ component (figure \ref{fig1}) in the source where \cite[Bianchi et al.(2007)]{Bianchi et al.(2007)} identified the AGN in an HST optical image. We also found a broad $H\beta$ feature (figure \ref{fig2}), but its emission reveals a extended source. We suggest that it is the light of the AGN scattered in the ionization cone. We propose that NGC 7582 is a Seyfert 1 galaxy. A number of other "hot-spots" and Wolf-Rayet features were also identified.Comment: 1 page, 2 figures, to be published in the Proceedings of the IAU Symposium no. 26

An atlas of Calcium triplet spectra of active galaxies

We present a spectroscopic atlas of active galactic nuclei covering the region around the 8498, 8542, 8662 Calcium triplet (CaT) lines. The sample comprises 78 objects, divided into 43 Seyfert 2s, 26 Seyfert 1s, 3 Starburst and 6 normal galaxies. The spectra pertain to the inner ~300 pc in radius, and thus sample the central kinematics and stellar populations of active galaxies. The data are used to measure stellar velocity dispersions (sigma_star) both with cross-correlation and direct fitting methods. These measurements are found to be in good agreement with each-other and with those in previous studies for objects in common. The CaT equivalent width is also measured. We find average values and sample dispersions of W_CaT of 4.6+/-2.0, 7.0 and 7.7+/-1.0 angstrons for Seyfert 1s, Seyfert 2s and normal galaxies, respectively. We further present an atlas of [SIII]\lambda 9069 emission line profiles for a subset of 40 galaxies. These data are analyzed in a companion paper which addresses the connection between stellar and Narrow Line Region kinematics, the behaviour of the CaT equivalent width as a function of sigma_star, activity type and stellar population properties.Comment: 18 pages, 10 figures, accepted for publication in MNRA

Commentary on "Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies" by Sievers et al.

Drug Delivery Technolog

Blueprint for mechanistic, data-rich early phase clinical pharmacology studies in dermatology

Drug Delivery Technolog

Commentary: anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave

Drug Delivery Technolog

Under-representation of elderly in clinical trials: an analysis of the initial approval documents in the Food and Drug Administration database

Aims To evaluate the availability of pharmacokinetic, safety and efficacy analyses specifically targeted at elderly, prior to the authorization of drugs. Methods A cross-sectional, structured review of publicly available initial approval documents of Food and Drug Administration-approved drugs was performed. The 10 most frequently on-label prescribed drug classes, drugs with known pharmacokinetic differences in the elderly or drugs that are relatively contraindicated in elderly (e.g. anticholinergics or benzodiazepines) were included in the analyses. Results In total, 1129 unique active pharmaceutical ingredients were found eligible for the analyses, of these, 506 were found in the Food and Drug Administration database (45%). The initial approval documents were available for 182 drugs. For the majority of the drugs, the initial approval documents in the database showed information on pharmacokinetics in elderly (n = 113; 62%). Furthermore, over time, the availability of information with regard to elderly increased statistically significantly from 0% in the period 1970-1979 to 76% for the period 2010-2018. Information on safety and efficacy was less frequently present, i.e. 42% and 45%, respectively and, moreover, the availability of information did not improve over time. Conclusion The under-representation of elderly in clinical trials thereby challenging the external validity of benefit/risk assessments of launched drugs was confirmed. Priority should be given to a study population that is representative for the target population.Drug Delivery Technolog

Complement activation in inflammatory skin diseases

The complement system is a fundamental part of the innate immune system, playing a crucial role in host defense against various pathogens, such as bacteria, viruses, and fungi. Activation of complement results in production of several molecules mediating chemotaxis, opsonization, and mast cell degranulation, which can contribute to the elimination of pathogenic organisms and inflammation. Furthermore, the complement system also has regulating properties in inflammatory and immune responses. Complement activity in diseases is rather complex and may involve both aberrant expression of complement and genetic deficiencies of complement components or regulators. The skin represents an active immune organ with complex interactions between cellular components and various mediators. Complement involvement has been associated with several skin diseases, such as psoriasis, lupus erythematosus, cutaneous vasculitis, urticaria, and bullous dermatoses. Several triggers including auto-antibodies and micro-organisms can activate complement, while on the other hand complement deficiencies can contribute to impaired immune complex clearance, leading to disease. This review provides an overview of the role of complement in inflammatory skin diseases and discusses complement factors as potential new targets for therapeutic intervention

Under-representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database

Aims: To evaluate the availability of pharmacokinetic, safety and efficacy analyses specifically targeted at elderly, prior to the authorization of drugs. Methods: A cross‐sectional, structured review of publicly available initial approval documents of Food and Drug Administration‐approved drugs was performed. The 10 most frequently on‐label prescribed drug classes, drugs with known pharmacokinetic differences in the elderly or drugs that are relatively contraindicated in elderly (e.g. anticholinergics or benzodiazepines) were included in the analyses. Results: In total, 1129 unique active pharmaceutical ingredients were found eligible for the analyses, of